clinical trials for tirzepatide New trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss CagriSema vs tirzepatide: which next-generation

Regular medical follow up is important for anyone taking these drugs over time

Those of us whose tax dollars supported his curiosity are the beneficiaries

Boost your vitality and take control of your well-being today

TK Tariq Khalil

Last reviewed: June 15, 2026 Last updated: June 15, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations

Vascular endothelial growth factor (VEGF) is a major factor in embryonic development and regulation of physiological angiogenesis for reproductive function